Electronic monitoring of patient adherence to oral antihypertensive medical treatment: A systematic review

Journal of Hypertension

Volumn 27, Issue 8, 2009, Pages 1540-1551

  Christensen, Arne ^a,b,c   Osterberg, Lars G ^d,e   Hansen, Ebba Holme ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Research Centre for Quality in Medicine Use   (Denmark)

^c BANG AND OLUFSEN A S   (Denmark)

^d STANFORD UNIVERSITY   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Antihypertensive medication; Electronic monitoring; Hypertension; Medication Event Monitoring System; MEMS; Patient adherence; Patient compliance

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC DISEASE; DEVICE; DOCTOR PATIENT RELATION; ELECTRONIC MONITORING; ELECTRONICS; FEEDBACK SYSTEM; HUMAN; HYPERTENSION; MEDICAL LITERATURE; MICROELECTROMECHANICAL SYSTEM; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 68449103666     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832d50ef     Document Type: Article

References (156)

1. Whitworth JA. 2003 World Health Organization (WHO)/lnternational Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
3. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 2006; 355:385-392.
4. Mendis S, Salas M. Hypertension [chapter XIII]. In: Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003. pp. 107-114.
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
6. Wetzeis GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22:1849-1855.
7. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008:CD000011.
8. Pharmionic systems, http://www.iadherence.org/mainPage.action?maintab= 3;2008.
9. Bang & Olufsen Medicom a/s. http://www.medicomnordic.com/sw4851. asp;2008.
10. Haynes RB, Wang E, Da Mota Gomes M. A critical review of interventions to improve compliance with prescribed medications. Patient Educ Courts 1987; 10:155-166.
11. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348:383-386.
12. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2000:CD000011.
13. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002:CD000011.
14. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005:CD000011.
15. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ, Evidence-Based Medicine Working Group. Users' guides to the medical literature. IX. A method for grading healthcare recommendations. JAMA 1995; 274:1800-1804.
16. Denhaerynck K, Schafer-Keller P, Young J, Steiger J, Bock A, De GS. Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients. BMC Med Res Methodol 2008; 8:5.
17. Mayo E. Hawthorne and the Western Electric Company, the social problems of an industrial civilization. New York, USA: Routledge; 1949.
18. Eisen SA, Woodward RS, Miller D, Spitznagel E, Windham CA. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987; 2:298-305.
19. Santschi V, Wuerzner G, Schneider MP, Bugnon O, Burnier M. Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. Eur J Clin Pharmacol 2007; 63:1179-1184.
20. Schroeder K, Fahey T, Hay AD, Montgomery A, Peters TJ. Adherence to antihypertensive medication assessed by self-report was associated with electronic monitoring compliance. J Clin Epidemiol 2006; 59:650-651.
21. Schroeder K, Fahey T, Hollinghurst S, Peters TJ. Nurse-led adherence support in hypertension: a randomized controlled trial. Earn Pract 2005; 22:144-151.
22. Rudd P, Miller NH, Kaufman J, Kraemer HC, Bandura A, Greenwald G, et al. Nurse management for hypertension. A systems approach. Am J Hypertens 2004; 17:921-927.
23. Ogedegbe G, Schoenthaler A, Richardson T, Lewis L, Belue R, Espinosa E, et al. An RCT of the effect of motivational interviewing on medication adherence in hypertensive African Americans: rationale and design. Contemp Clin Trials 2007; 28:169-181.
24. Schoenthaler A, Ogedegbe G. Patients' perceptions of electronic monitoring devices affect medication adherence in hypertensive African Americans. Ann Pharmacother 2008; 42:647-652.
25. Gerin W, Tobin JN, Schwartz JE, Chaplin W, Rieckmann N, Davidson KW, et al. The medication Adherence and Blood Pressure Control (ABC) trial: a multisite randomized controlled trial in a hypertensive, multicultural, economically disadvantaged population. Contemp Clin Trials 2007; 28:459-471.
26. Vander Stichele RH, Thomson M, Verkoelen K, Droussin A. Measuring patient compliance with electronic monitoring: lisinopril versus atenolol in essential hypertension. Postmark Surv 1992; 6:77-90.
27. Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials 1997; 18:187-203.
28. Smith DM, Diggle PJ. Compliance in an antihypertension trial: a latent process model for binary longitudinal data. Stat Med 1998; 17:357-370.
29. Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens 2000; 13:184-190.
30. Baulmann J, Dusing R, Vetter H, Mengden T. Therapy resistant hypertension: significance of electronic compliance monitoring. Dtsch Med Wochenschr 2002; 127:2379-2382.
31. Bertholet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M. Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens (Greenwich) 2000; 2:258-262.
32. Bogner HR, de Vries HF. Integration of depression and hypertension treatment: a pilot, randomized controlled trial. Ann Earn Med 2008; 6:295-301.
33. Bovet P, Burnier M, Madeleine G, Waeber B, Paccaud F. Monitoring one-year compliance to antihypertension medication in the Seychelles. Bull World Health Organ 2002; 80:33-39.
34. Brunenberg DE, Wetzels GE, Nelemans PJ, Dirksen CD, Severens JL, Stoffers HE, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics 2007; 25:239-251.
35. Braam RL, van Uum SH, Lenders JW, Thien T. Bromide as marker for drug adherence in hypertensive patients. Br J Clin Pharmacol 2008; 65:733-736.
36. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19:335-341.
37. Chiolero A, Santschi V, Burnier M. Treatment compliance, key element in the management of arterial hypertension. Rev Med Suisse Romande 2002; 122:237-240.
38. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37:846-857.
39. Choo PW, Rand CS, Inui TS, Lee ML, Ma CC, Platt R. A pharmacodynamic assessment of the impact of antihypertensive nonadherence on blood pressure control. Pharmacoepidemiol Drug Saf 2000; 9:557-563.
40. Choo PW, Rand CS, Inui TS, Lee ML, Canning C, Platt R. A cohort study of possible risk factors for over-reporting of antihypertensive adherence. BMC Cardiovasc Disord 2001; 1:6.
41. Detry JM, Block P, De BG, Degaute JP, The Belgian Collaborative Study Group. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol 1995; 47:477-481.
42. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150:1881-1884.
43. Falconnet C, Bochud M, Bovet P, Maillard M, Burnier M. Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent. J Hypertens 2004; 22:1213-1220.
44. Girvin B, Johnston GD. A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. J Hypertens 1998; 16:1049-1054.
45. Girvin B, McDermott BJ, Johnston GD. A comparison of enalapril 20 mg once daily versus 10 mg twice daily in terms of blood pressure lowering and patient compliance. J Hypertens 1999; 17:1627-1631.
46. Girvin BG, Johnston GD. Comparison of the effects of a 7-day period of noncompliance on blood pressure control using three different antihypertensive agents. J Hypertens 2004; 22:1409-1414.
47. Guerrero D, Rudd P, Bryant-Kosling C, Middleton B, Middleton BF, corrected to Middleton. Antihypertensive medication-taking. Investigation of a simple regimen. Am J Hypertens 1993; 6 (7 Pt 1):586-592.
48. Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003; 2:219-228.
49. Kruse W, Rampmaier J, Ullrich G, Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994; 32:452-457.
50. Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 1996; 9:719-725.
51. Leenen FH, Wilson TW, Bolli P, Larochelle P, Myers M, Handa SP, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997; 13:914-920.
52. Lueg MC, Herron J, Zellner S. Transdermal clonidine as an adjunct to sustained-release diltiazem in the treatment of mild-to-moderate hypertension. Clin Ther 1991; 13:471-481.
53. Magometschnigg D. Patient compliance of hypertensive patients in the physician's practice. Wien Med Wochenschr 1995; 145:360-364.
54. Magometschnigg D, Hitzenberger G. Compliance of the hypertensive patient in medical practice: analysis of an observation study. 2 [in German]. Wien Med Wochenschr 1997; 147:525-528.
55. Mallion JM, Meilhac B, Tremel F, Calvez R, Bertholom N. Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment. J Cardiovasc Pharmacol 1992; 19 (Suppl 2): S41-S48.
56. Mallion JM, Dutrey-Dupagne C, Vaur L, Genes N, Renault M, Baguet P, et al. Behavior of patients with mild-to-moderate arterial hypertension in relation to their treatment. Contribution of an electronic pillbox. Ann Cardiol Angeiol (Paris) 1995; 44:597-605.
57. Mallion JM, Dutrey-Dupagne C, Vaur L, Genes N, Renault M, Elkik F, et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens 1996; 14:137-144.
58. Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, de la Figuera-Von Wichmann M, Casado-Martinez JJ, Martin-de Pablos JL, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens 2006; 24:169-175.
59. Mengden T, Binswanger B, Spuhler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993; 11:1403-1411.
60. Mengden T, Vetter H, Tousset E, Uen S. Management of patients with uncontrolled arterial hypertension: the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCT. BMC Cardiovasc Disord 2006; 6:36.
61. Mounier-Vehier C, Bernaud C, Carre A, Lequeuche B, Hotton JM, Charpentier JC. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Am J Hypertens 1998; 11(4 Pt 1): 478-486.
62. Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ 2001; 323:142-146.
63. Petri H, Urquhart J. Patient compliance with beta-blocker medication in general practice. Pharmacoepidemiol Drug Saf 1994; 3:251-256.
64. Qureshi NN, Hatcher J, Chaturvedi N, Jafar TH. Effect of general practitioner education on adherence to antihypertensive drugs: cluster randomised controlled trial. BMJ 2007; 335:1030.
65. Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol 2000; 14:1083-1087.
66. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48:676-685.
67. Santschi V, Rodondi N, Bugnon O, Burnier M. Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. Eur J Intern Med 2008; 19:427-434.
68. Vaur L, Dubroca II, Dutrey-Dupagne C, Genes N, Chatellier G, Bouvier-d'Yvoire M, et al. Superiority of home blood pressure measurements over office measurements for testing antihypertensive drugs. Blood Press Monit 1998; 3:107-114.
69. Vaur L, Vaisse B, Genes N, Elkik F, Legrand C, Poggi L. Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. Am J Hypertens 1999; 12 (4 Pt 1):374-380.
70. Verberk WJ, Kroon AA, Kessels AG, Dirksen C, Nelemans PJ, Lenders JW, et al. Home versus office blood pressure measurements: reduction of unnecessary treatment study - rationale and study design of the HOMERUS trial. Blood Press 2003; 12:326-333.
71. Waeber B, Leonetti G, Kolloch R, Mclnnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999; 17:1041-1045.
72. Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract 1999; 53:37-38.
73. Weidler D, Wallin JD, Cook E, Dillard D, Lewin A. Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance. J Clin Pharmacol 1992; 32:444-449.
74. Wetzels G, Nelemans P, van WB, Broers N, Schouten J, Prins M. Determinants of poor adherence in hypertensive patients: development and validation of the 'Maastricht Utrecht Adherence in Hypertension (MUAH)-questionnaire'. Patient Educ Couns 2006; 64:151-158.
75. Wetzels GE, Nelemans PJ, Schouten JS, van Wijk BL, Prins MH. All that glisters is not gold: a comparison of electronic monitoring versus filled prescriptions - an observational study. BMC Health Serv Res 2006; 6:8.
76. Wetzels GE, Nelemans PJ, Schouten JS, Dirksen CD, van der WT, Stoffers HE, et al. Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens 2007; 20:119-125.
77. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19:1855-1860.
78. Zeller A, Schroeder K, Peters TJ. Electronic pillboxes (MEMS) to assess the relationship between medication adherence and blood pressure control in primary care. Scand J Prim Healthcare 2007; 25:202-207.
79. Zeller A, Schroeder K, Peters TJ. An adherence self-report questionnaire facilitated the differentiation between nonadherence and nonresponse to antihypertensive treatment. J Clin Epidemiol 2008; 61:282-288.
80. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117.
81. Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Methods Med Res 1999; 8:247-262.
82. Vrijens B, Goetghebeur E. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies. Stat Med 2004; 23:531-544.
83. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004:CD004804.
84. Artinian NT, Harden JK, Kronenberg MW, Vander Wal JS, Daher E, Stephens Q, Bazzi RI. Pilot study of a web-based compliance monitoring device for patients with congestive heart failure. Heart Lung 2003; 32:226-233.
85. Bohachick P, Burke LE, Sereika S, Murali S, Dunbar-Jacob J. Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure. Prog Cardiovasc Nurs 2002; 17:160-166.
86. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994; 22:266-272.
87. Chand DH, Bednarz D. Daily remote peritoneal dialysis monitoring: an adjunct to enhance patient care. Perit Dial Int 2008; 28:533-537.
88. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150:1509-1510.
89. Detry JM, Block P, De BG, Degaute JP, Six R. Patient compliance and therapeutic coverage: amlodipine versus nifedipine (slow-release) in the treatment of angina pectoris. Belgian Collaborative Group. J Int Med Res 1994; 22:278-286.
90. Dunbar-Jacob J, Bohachick P, Mortimer MK, Sereika SM, Foley SM. Medication adherence in persons with cardiovascular disease. J Cardiovasc Nurs 2003; 18:209-218.
91. Erne P, Saxenhofer H, Waeber B, Heynen G. Time of drug intake in hypertension and angina pectoris. A controlled monitoring study. Schweiz Rundsch Med Prax 1994; 83:1079-1083.
92. Feldman HI, Hackett M, Bilker W, Strom BL. Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents. Pharmacoepidemiol Drug Saf 1999; 8:1-14.
93. Gold DT. Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. J Manag Care Pharm 2006; 12 (6 Suppl A):S20-S25.
94. Holzgreve H. Therapietreue elektronisch überwacht. Münchner Medizinische Wochenschrift 2007; 2007.
95. Koehler AM, Maibach HI. Electronic monitoring in medication adherence measurement. Implications for dermatology. Am J Clin Dermatol 2001; 2:7-12.
96. Kruse W, Weber E. Dynamics of drug regimen compliance: its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38:56-565.
97. Miller NH, Warren D, Myers D. Home-based cardiac rehabilitation and lifestyle modification: the MULTIFIT model. J Cardiovasc Nurs 1996; 11:76-87.
98. Murray MD, Young JM, Morrow DG, Weiner M, Tu W, Hoke SC, et al. Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure. Am J Geriatr Pharmacother 2004; 2:53-65.
99. Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9:iii-163.
100. Pruijm MT, Teta D, Wuerzner G, Santschi V, Burnier M. Treatment of secondary hyperparathyroidism in dialysis: report of a case-study of treatment failure. Nephrol Ther 2008; 4:28-33.
101. Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante T, Musig A, Gandolfo E. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006; 47:2917-2923.
102. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144:533-540.
103. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992; 22:238-246.
104. Rudd P, Ramesh J, Bryant-Kosling C, Guerrero D. Gaps in cardiovascular medication taking: the tip of the iceberg. J Gen Intern Med 1993; 8:659-666.
105. Santschi V, Rodondi N, Bugnon O, Pannatier A, Burnier M. Monitoring drug adherence for hypertensive and dyslipidemic patients in networks of community-based pharmacists and physicians. Rev Med Suisse 2008; 4:1928, 1930-1932, 1934.
106. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005; 16: 114-121.
107. Tu W, Morris AB, Li J, Wu J, Young J, Brater DC, Murray MD. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther 2005; 77:189-201.
108. Vrijens B, Goetghebeur E. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies. Stat Med 2004; 23:531-544.
109. Waeber B, Erne P, Saxenhofer H, Heynen G. Use of drugs with more than a twenty-four-hour duration of action. J Hypertens Suppl 1994; 12:S67-S71.
110. Wallen NH, Andersson A, Hjemdahl P. Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris. Br J Clin Pharmacol 1994; 38:63-70.
111. Yamada H, Sesoko S, Daimon T, Nakashima M. Application of a newly designed electronic monitoring device for press through packaging sheets in a clinical trial. Br J Clin Pharmacol 2006; 61:238-239.
112. Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl 2003; 21:S37-S42.
113. Campbell NR, Abbott D, Bass M, Birkett NJ, Chockalingam A, Dagenais GR, et al. Self-measurement of blood pressure: recommendations of the Canadian coalition for high blood pressure prevention and control. Can J Cardiol 1995; 11(Suppl H):5H-17H.
114. Cramer J. Medicine partnerships. Heart 2003; 89 (Suppl 2):ii19-ii21.
115. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49:321-327.
116. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 1998; 4:1563-1568.
117. Detry-Morel M. Compliance and persistence. J Fr Ophtalmol 2006; 29:216-225.
118. Ferrer RL, Sibai BM, Mulrow CD, Chiquette E, Stevens KR, Cornell J. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 2000; 96 (5 Pt 2):849-860.
119. Girvin B, Johnston GD. The implications of noncompliance with antihypertensive medication. Drugs 1996; 52:186-195.
120. Mallion JM, Baguet JP, Siche JP, Tremel F, de GR. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens Suppl 1998; 16:S75-S79.
121. Marquez Contreras E, Gil Guillen V, Casado Martinez JJ, Martel Claras N, De la Figuera von Wichmann M, Martin de Pablos JL, et al. Analysis of studies published on hypertension treatment non-compliance in Spain between 1984 and 2005. Aten Primaria 2006; 38:325-332.
122. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130 (3 Pt 1):572-579.
123. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164:722-732.
124. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004:CD004804.
125. Viera AJ, Jamieson B, Dealleaume L Clinical inquiries. How effective are hypertension self-care interventions? J Fam Pract 2007; 56:229-231.
126. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117.
127. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21:973-985.
128. Wetzeis GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22:1849-1855.
129. Willey C. Behavior-changing methods for improving adherence to medication. Curr Hypertens Rep 1999; 1:477-481.
130. Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2000; 2:510-514.
131. Austin DL. Selected nursing interventions for noncompliant hypertensive patients. Dissertation Abstr Int 1986; 47:1925.
132. Blagova OV, Nedostup AV. Characteristics of action of various drugs blocking atrioventricular conduction (beta-blockers, verapamil, diltiazem) in constant fibrillation tachyarrhythmia. Is monotherapy optimal?. Ter Arkh 2006; 78:30-38.
133. Bosworth HB, Olsen MK, Dudley T, Orr M, Neary A, Harrelson M, et al. Take Control of Your Blood pressure (TCYB) study: study design and methodology. Contemp Clin Trials 2007; 28:33-47.
134. Cohen SJ, Weinberger MH, Fineberg NS, Miller JZ, Grim CE, Luft FC. The effect of a household partner and home urine monitoring on adherence to a sodium restricted diet. Soc Sci Med 1991; 32:1057-1061.
135. Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J, Carey K. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens 1996; 9 (4 Pt 1):285-292.
136. Herpin D, Mallion JM, Benkritly A, Baguet JP, Tremel F. The Hypertension Optimal Treatment Study: efficacy and tolerability on the 36th month. Arch Mal Coeur Vaiss 1998; 91:1043-1048.
137. Hunt JS, Siemienczuk J, Touchette D, Payne N. Impact of educational mailing on the blood pressure of primary care patients with mild hypertension. J Gen Intern Med 2004; 19:925-930.
138. Johnson BF, Hamilton G, Fink J, Lucey G, Bennet N, Lew R. A design for testing interventions to improve adherence within a hypertension clinical trial. Control Clin Trials 2000; 21:62-72.
139. Johnson SS, Driskell MM, Johnson JL, Prochaska JM, Zwick W, Prochaska JO. Efficacy of a transtheoretical model-based expert system for antihypertensive adherence. Dis Manage 2006; 9:291-301.
140. Karotsis AK, Symeonidis A, Mastorantonakis SE, Stergiou GS. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. Clin Exp Hypertens 2006; 28: 655-662.
141. Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 1996; 9:719-725.
142. McKenney JM, Munroe WP, Wright JT, Jr. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol 1992; 32:277-283.
143. Murray MD, Young JM, Morrow DG, Weiner M, Tu W, Hoke SC et al. Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure. Am J Geriatr Pharmacother 2004; 2:53-65.
144. Ornstein SM, Jenkins RG. Quality of care for chronic illness in primary care: opportunity for improvement in process and outcome measures. Am J Manag Care 1999; 5:621-627.
145. Rabinowitz I, Tamir A. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care: cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record. Eur J Cardiovasc Prev Rehabil 2005; 12:56-62.
146. Rogers MA, Small D, Buchan DA, Butch CA, Stewart CM, Krenzer BE, Husovsky HL. Home monitoring service improves mean arterial pressure in patients with essential hypertension. A randomized, controlled trial. Ann Intern Med 2001; 134:1024-1032.
147. Sato S. Quantitative evaluation of ontogenetic change in heart rate and its autonomic regulation in newborn mice with the use of a noninvasive piezoelectric sensor. Am J Physiol Heart Circ Physiol 2008; 294:H1708-H1715.
148. Verberk WJ, Kroon AA, Kessels AG, Nelemans PJ, Van Ree JW, Lenders JW, et al. Comparison of randomization techniques for clinical trials with data from the HOMERUS-trial. Blood Press 2005; 14:306-314.
149. White WB, Mansoor GA, Pickering TG, Vidt DG, Hutchinson HG, Johnson RB, Noveck R. Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. Am J Hypertens 1999; 12 (8 Pt 1):806-814.
150. Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther 2000; 22:858-871.
151. Boaventura I, Coelho R, Rocha-Goncalves F. Compliance to therapy: its importance in research and clinical practice. Rev Port Cardiol 1994; 13:677-683, 640. (No primary research)
152. Burattini R, Fogliardi R, Campbell KB. Lumped model of terminal aortic impedance in the dog. Ann Biomed Eng 1994; 22:381-391. (Population not human)
153. Eisen SA, Hanpeter JA, Kreuger LW, Gard M. Monitoring medication compliance: description of a new device. J Compliance Health Care 1987; 2:131-142. (Device description)
154. Schroeder K, Fahey T, Ebrahim S, Peters TJ. Adherence to long-term therapies: recent WHO report provides some answers but poses even more questions. J Clin Epidemiol 2004; 57:2-3. (Commentary)
155. Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Methods Med Res 1999; 8:247-262. (No primary research)
156. Waeber B. What has been learned from electronic monitoring of compliance with antihypertensive medications? J Hypertens 2004; 22:1857-1858. (Commentary)